The presence of phosphorylated Cdc27 in cancer cells is utilized to identify patients likely to benefit from treatment with a chemotherapeutic agent that binds to, or binds to and crosslinks, phosphorylated Cdc27, e.g., curcumin, or to determine whether patients undergoing such treatment will continue to respond effectively. Candidate compounds are screened for anticancer effect by testing the ability to bind to or crosslink phosphorylated Cdc27.
